Nurix Therapeutics, Inc. 8-K

What Happened

• On March 6, 2026, Nurix Therapeutics, Inc. announced Amendment No. 3 to its equity distribution agreement with Piper Sandler & Co., allowing the company to offer and sell, from time to time, up to $413.65 million of its common stock through an "at-the-market" (ATM) program. The amount includes shares previously sold under the agreement following prior amendments. The offering is being made under Nurix’s Automatic Shelf Registration Statement on Form S-3 and related prospectus supplements.

Key Details

• Amendment No. 3 executed: March 6, 2026.
• Aggregate ATM capacity: $413.65 million (includes shares already sold under prior amendments).
• Sales agent: Piper Sandler & Co.; security: common stock, $0.001 par value per share.
• Offering documents: Automatic Shelf Registration Statement (Form S-3, File No. 333-280117) and prospectus supplements (original Oct 31, 2024; Amendment No. 1 dated Mar 6, 2026).
• Exhibits filed with the 8‑K: Amendment No. 3 (Exhibit 10.1) and legal opinion of Fenwick & West LLP regarding the shares (Exhibit 5.1).

Why It Matters

• The ATM program gives Nurix a flexible way to raise equity capital over time, selling shares into the market as needed and as market conditions permit. For investors, this can mean potential dilution if the company elects to issue shares, but it also provides the company with access to funding without negotiating a single large follow‑on offering. The 8‑K does not commit Nurix to sell any specific amount of shares and sales would be subject to market conditions and regulatory requirements.